Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands.
ISA Pharmaceuticals, Leiden, Netherlands.
Front Immunol. 2020 Nov 6;11:579022. doi: 10.3389/fimmu.2020.579022. eCollection 2020.
Autoreactive CD8 T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antigens in the skin. Therapeutically enhancing immune checkpoint signaling by immune cells or skin cells, making self-reactive T cells anergic, seems a promising therapeutic option for vitiligo. Here, we review the current knowledge on the PD-1/PD-L1 pathway in vitiligo as new therapeutic target for vitiligo therapy.
自身反应性 CD8 T 细胞在自身免疫性白癜风的黑素细胞破坏中起关键作用。免疫疗法治疗黑色素瘤常导致自身免疫性副作用，其中包括白癜风样脱色素，表明靶向免疫检查点可以破坏皮肤中针对自身抗原的外周耐受。通过免疫细胞或皮肤细胞增强免疫检查点信号，使自身反应性 T 细胞无反应性，似乎是白癜风的一种有前途的治疗选择。在这里，我们回顾了 PD-1/PD-L1 通路在白癜风中的最新知识，将其作为白癜风治疗的新治疗靶点。
